Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(8/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(8/week)
News
United States
(492/week)
Manufacturing
(332/week)
Energy
(271/week)
Technology
(348/week)
Other Energy
(234/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Seqirus
Dec 09, 2020
Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020
Dec 07, 2020
Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Benefits of MF59®-Adjuvanted Seasonal Influenza Vaccine
Oct 29, 2020
Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza Vaccine (QIVc) Efficacy in Children >=2 to <18 Years Old at the European Society for Paediatric Infectious Diseases (ESPID)
Oct 21, 2020
Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020
Oct 21, 2020
Seqirus Announces Late-Breaking Data at IDWeek 2020: New Real-World Evidence Shows Value of Adjuvanted Influenza Vaccine for Adults 65 Years and Older with Underlying Health Conditions
Jul 30, 2020
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market
Feb 24, 2020
Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older
Dec 09, 2019
New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine
Aug 31, 2019
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Aug 30, 2019
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
Aug 22, 2019
Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines at OPTIONS X Conference
Apr 15, 2019
Seqirus Announces Further Advances in Cell-Based Influenza Vaccine Technology
Nov 16, 2018
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
Nov 16, 2018
Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options
Oct 23, 2018
Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
Oct 03, 2018
Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek
Oct 03, 2018
Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines
Aug 23, 2018
Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process
Jul 26, 2018
GISAID announces a major contribution from Seqirus to support open and rapid sharing of influenza virus data
Apr 19, 2018
The Lancet publishes results demonstrating adjuvanted quadrivalent influenza vaccine provides significantly greater efficacy in children 6 through 23 months
Page 1
››
Latest News
Apr 18, 2024
Jacam Catalyst to Showcase Pioneering Oilfield Chemical Solutions on “Inside the Blueprint”
Apr 18, 2024
Defense Technology Company, Allen Control Systems, Raises $12 Million Seed Capital to Build Counter-Drone...
Apr 18, 2024
SWTCH Energy Secures $27.2M in Series B Funding to Eliminate EV Charging Gaps in Buildings
Apr 18, 2024
Catalyze Announces Commercial Operation of Renewable Energy Installations for 66 Galen
Apr 18, 2024
Cabot Corporation and Partners Selected for $5M in U.S. Department of Energy Grant to Support Continued...
Apr 18, 2024
General Mills Stands for People and Planet in 2024 Global Responsibility Report
Apr 18, 2024
BZI Named by USA TODAY as a Top Workplace in the Nation
Apr 18, 2024
Denis Johnson Joins Kindeva Drug Delivery as Chief Operating Officer to Lead Global Operations
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events